Erythropoietin Signaling: A Novel Regulator of White Adipose Tissue Inflammation During Diet-Induced Obesity

Diabetes 2014;63:2415–2431 | DOI: 10.2337/db13-0883

Obesity-induced white adipose tissue (WAT) inflammation and insulin resistance are associated with macrophage (Mφ) infiltration and phenotypic shift from “anti-inflammatory” M2-like to predominantly “proinflammatory” M1-like cells. Erythropoietin (EPO), a glycoprotein hormone indispensable for erythropoiesis, has biological activities that extend to nonerythroid tissues, including antiapoptotic and anti-inflammatory effects. Using comprehensive in vivo and in vitro analyses in mice, EPO treatment inhibited WAT inflammation, normalized insulin sensitivity, and reduced glucose intolerance. We investigated EPO receptor (EPO-R) expression in WAT and characterized the role of its signaling during obesity-induced inflammation. Remarkably, and prior to any detectable changes in body weight or composition, EPO treatment reduced M1-like Mφ and increased M2-like Mφ in WAT, while decreasing inflammatory monocytes. These anti-inflammatory effects were found to be driven, at least in part, by direct EPO-R response in Mφ via Stat3 activation, where EPO effects on M2 but not M1 Mφ required interleukin-4 receptor/Stat6. Using obese ΔEpoR mice with EPO-R restricted to erythroid cells, we demonstrated an anti-inflammatory role for endogenous EPO. Collectively, our findings identify EPO-R signaling as a novel regulator of WAT inflammation, extending its nonerythroid activity to encompass effects on both Mφ infiltration and subset composition in WAT.

Macrophage (Mφ) infiltration to white adipose tissue (WAT) during obesity marks a state of chronic inflammation, an important cause of obesity-induced insulin resistance and glucose intolerance (1–4). This chronic inflammatory response impacts type 2 diabetes pathogenesis (1,4) and associates with a shift in Mφ population from alternatively activated F4/80+MGL-1+ (anti-inflammatory) M2 to predominantly classically activated F4/80+MGL-1− (proinflammatory) M1 (5–8) in association with recruitment from circulating “inflammatory” Ly6C(hi)CCR2+ monocytes to Mφ clusters in WAT via CCL2/CCR2 axis and not to the conversion of resident M2 Mφ to M1 (1,3,5,6,8–10).

Mφ infiltration and activation state influence inflammation-induced insulin resistance and glucose intolerance during diet-induced obesity (DIO) (11–13). It is suggested that Mφ may be an initiator in insulin-resistant states and that, with their precursors, may contribute to propagation of insulin resistance (11–17). Mφ infiltration to WAT requires and kinetically follows CD8+ T lymphocytes recruitment (18). Obesity-induced inflammation and immune cell infiltration elevate cytokines and chemokines such as tumor necrosis factor (TNF)-α and CCL2, systemically and locally in WAT, where cells of the stromal vascular fraction (SVF), including Mφ, are known to be the main producers, particularly in visceral fat depots (1,3,4,19–21). Signaling of such inflammatory mediators...
is adversely implicated in the impairment of systemic glucose metabolism (1,5).

Erythropoietin (EPO) is a glycoprotein hormone induced by hypoxia and necessary for erythrocyte production (22–24). EPO is used for treatment of anemia in chronic kidney disease, including type 2 diabetic patients (25). Its biological activity extends beyond regulating erythropoiesis, and the nonerythroid expression of EPO receptor (EPO-R) has been reported (26). Although, proposed to occur via antiapoptotic rather than “direct” anti-inflammatory effects on cells of the immune system (32), it can also occur directly via inhibiting Mφ infiltration and inhibit inflammation (33). Although, proposed to occur via antiapoptotic rather than “direct” anti-inflammatory effects on cells of the immune system (32), it can also occur directly via inhibiting Mφ and/or activating immune suppressive lymphocytes (33,34).

Early treatment of mice with exogenous EPO at the onset of high-fat diet (HFD) feeding or EPO transgenic overexpression halts body weight and fat mass gain and improves glucose tolerance (35–38). Using ΔEpoR mice with EPO-R restricted to erythroid tissue (39), we previously showed EPO-R absence in WT contributes directly to obesity and glucose intolerance on normal chow (36). EPO protects against diabetes through direct effects on pancreatic β-cells in mouse models of type 1 and 2 diabetes (36,37,40). It remains unknown whether anti-inflammatory EPO effects in WAT contribute to EPO effects on the pre-diabetic state during obesity.

In this study, we hypothesized that EPO/EPO-R signaling can attenuate obesity-induced WAT inflammation. Our findings identify a novel role for EPO in regulating inflammatory monocyte recruitment and Mφ infiltration and activation during DIO.

RESEARCH DESIGN AND METHODS

Animals and Animal Care

Wild-type (WT) male C57BL/6 mice were obtained from National Cancer Institute Institute Animal Production Program (Frederick, MD). Mice with EPO-R expression restricted to hematopoietic tissue (ΔEpoR) were provided by Masayuki Yamamoto (Tohoku University, Japan). EPO-R expression in ΔEpoR mice arises from transgene expression of EpoR cDNA driven by the erythroid specific enhancer/promoter of GATA-1 on C57BL/6 EpoR+/− background (29). Male Stat6−/− (Stat6tm1Gru) and interleukin (IL)-4−/− (Il4tm1Nnt) mice on C57BL/6 background and their age-matched WT controls were obtained from The Jackson Laboratory (JAX mice) (Bar Harbor, ME). Mice were fed control diet (10 kcal% fat) or, to induce DIO, HFD containing 60 kcal% fat (high fat, 5,240 kcal/kg, 34.9% crude fat; Research Diets Inc., New Brunswick, NJ) starting at 6–8 weeks of age for 12 weeks. During the last 2 weeks of the study period, obese, insulin-resistant, and glucose-intolerant mice were subcutaneously injected with 1,000 units/kg EPO (EPO dose was chosen based on our previous titration studies (35)) or saline as a vehicle control, every 48 h while continuing HFD feeding. At the end of week 12, the effects of 2 weeks EPO treatment on several metabolic and inflammatory parameters were assessed as described below. Animals were housed under specific pathogen-free conditions and maintained in a thermostated environment under a 12-h light/dark cycle with free access to food and water. All animal protocols were conducted under the National Institutes of Health guidelines and approved by the institute’s Animal Care and Use Committee.

Reagents and Antibodies

Reagents and antibodies include anti-F4/80 and anti-Ly6C antibodies (eBioscience); anti-MGL1/CD301 and anti-CCR2 (R&D Systems); Fc-block and anti-CD11c antibodies (BD Biosciences); rat anti-mouse Ki-67 antibody (BioLegend) used in combination with fluorescein isothiocyanate–conjugated goat anti-rat F(ab)2 (Santa Cruz Biotechnology Inc.); bromodeoxyuridine (BrdU; Sigma-Aldrich) and fluorescein isothiocyanate BrdU flow detection kit (BD Pharmingen); rabbit anti-mouse phospho (p)-Stat5 (Tyr694; C71E5) and p-Stat3 (Tyr705; D3A7) monoclonal antibodies (Cell Signaling Technology); mouse anti-mouse phospho-Stat6 (Tyr641; BD Biosciences); recombinant human Epoetin α or Epogen (EPO) (Amgen); Vectashield mounting media with DAPI (Vector Laboratories); and recombinant mouse cytokines GM-CSF, IL-4, and IL-10 (PeproTech).

Body Weight and Composition Measurements

Body weight was measured weekly from day 0 to week 12. Body composition analysis to determine fat and lean body mass was also performed using EchoMRI-100 system (Echo Medical Systems).

Hematocrit Measurement

Hematocrit was determined for saline- and EPO-treated animals after centrifugation of blood containing heparin coated capillary tubes, using VIN microcapillary tube reader (Veterinary Information Network Bookstore).

Metabolic Evaluation

Glucose tolerance tests (GTTs) were performed upon intraperitoneal injection with 1 g/kg dextrose. Insulin tolerance tests (ITTs) were performed after injection with 1 unit/kg insulin. Total blood and serum glucose measurements were made using AlphaTRAK glucometer (Abbott Animal Health). Serum insulin levels were measured using Sensitive Rat Insulin Radioimmunoassay (Millipore). Serum leptin levels were determined by ELISA (Millipore). Euglycemic–hyperinsulinemic clamp studies were performed in restrained mice fasted for 16 h as described previously (41).

SVF Cell Extraction

SVF cells were extracted as previously described (18). Briefly, perigonadal WAT were digested by collagenase type 2 ( Worthington) at 37°C for 50 min. WAT cell suspensions were spun at 500 g for 5 min to separate floating adipocytes from SVF pellet.

Gene Expression Analysis

Total RNA was extracted from cells or tissues using TRIzol (Invitrogen) and treated with DNase I (Fermentas)
In Vitro to assess Stat5, Stat3, and Stat6 phosphorylation. qRT-PCR analysis of EPO-R expression levels or cultured ware (BD Biosciences). Sorted WAT Mϕ previously described (8). Circulating in Flow Cytometry and Phospho-WAT Mϕ EPO Treatment of Sorted WAT Mϕ. Flow Cytometry and Phospho-WAT Mϕ were used for fluorescence-activated cell sorter (FACS) sorting and cell sorting and purification of Mϕ from SVF of obese mice (after 12 weeks of HFD feeding) according to manufacturers’ protocols. Two micrograms of total RNA was then reverse transcribed using MultiScribe Reverse Transcriptase for quantitative real-time PCR (qRT-PCR) assays using ABI 7900HT cycler (Applied Biosystems). For EPO-R gene expression analysis, mRNA was quantified using TaqMan qRT-PCR, with 16S and β-actin as controls. Relative changes in gene expression levels of inflammatory cytokines, chemokines, and receptors, in SVF of epididymal adipose tissue, were analyzed using mouse inflammatory cytokines and receptors RT² profiler PCR (SABiosciences, Qiagen). Briefly, cDNA was synthesized using RT² first strand reaction, and PCR was performed using RT² PCR master mix (SABiosciences, Qiagen). Four to six replicate 96-well plates were included per group; data analysis was performed using web-based PCR Array Data Analysis Software version 3.4 (SABiosciences, Qiagen). Changes in Mϕ subtype signature gene expression levels M1 (inducible nitric oxide synthase [iNOS] and IL-1β) and M2 (Fizz-1, Arg-1, peroxisome proliferator–activated receptor [Ppar]-γ) were assessed in SVF cells using sybergreen gene expression assays (Fermentas). Relative gene expression levels were determined by normalization to β-actin expression levels using the ΔΔCt method. Primer and probe sequences used are listed in Supplementary Table 1.

WAT and Serum Cytokine and Chemokine Protein Measurements

CCL2 levels were analyzed in perigonadal WAT tissue and serum; those for TNF-α, IL-10, and IL-4 were analyzed in serum by ELISA according to the manufacturer’s protocol (PeproTech).

Cell Sorting and Purification

WAT Mϕ were sorted by separation of F4/80+ (Mϕ) and F4/80− (non-Mϕ) fractions of stromal vascular cells using FACSARia fluorescent cell sorter and FACSDiva software (BD Biosciences). Sorted WAT Mϕ were used for qRT-PCR analysis of EPO-R expression levels or cultured to assess Stat5, Stat3, and Stat6 phosphorylation.

EPO Treatment of Sorted WAT Mϕ In Vitro

WAT Mϕ, fluorescence-activated cell sorter (FACS) sorted from SVF of obese mice (after 12 weeks of HFD feeding) was cultured in saline or EPO (5 units/mL)-coated 48-well plates at a density of 2 × 10^5 per well for 15 min then fixed, permeabilized, and tested for Stat3, Stat5a/b, and Stat6 phosphorylation by phosphoflow. Stimulation for 15 min with GM-CSF, IL-4, and IL-10 were used as positive controls for Stat5, Stat6, and Stat3 phosphorylation, respectively. In some studies, the sorted WAT Mϕ were cultured with EPO (5 units/mL) for 24 h, after which their TNF-α, iNOS, and IL-10 mRNA levels were quantified using sybergreen qRT-PCR.

Flow Cytometry and Phosphoflow

SVF of perigonadal WAT was analyzed by flow cytometry as previously described (8). Circulating inflammatory monocytes were quantified using Ly6C and CCR2 expression as previously described (42). Phosphoflow and staining for p-Stat3, p-Stat5a/b, and p-Stat6 were performed as previously described (43). Cell proliferation was assessed using Ki-67 detection and BrdU labeling. In vivo labeling with BrdU was achieved by supplementing drinking water with 0.8 mg/mL BrdU, starting 48 h prior to the first EPO injection during weeks 11 and 12 of HFD, for 9 consecutive days followed by a changeover to normal water until the end of week 12. FACScanibur and CellQuest (BD Biosciences) were used for flow cytometric and phosphoflow analyses.

Histology and Microscopy

Frozen sections of perigonadal fat pads were prepared after dissection and fixation in 10% formalin. Hematoxylin and eosin (H&E)-stained sections were imaged for crown-like structures. Immunofluorescence was performed for Mϕ detection by incubation en block with directly conjugated primary anti-F4/80 antibodies. All imaging analyses were performed on OLYMPUS IX70 inverted microscope (Optical Elements Corporation). Image capture was performed using SPOTFlex camera and SPOT Basic imaging software (Diagnostic Instruments Inc.), using 15 sections per group (n = 5 mice per group).

Statistical Analysis

Statistical comparisons were performed using Student t test, with P values <0.05 defined as statistically significant. Results are presented as mean ± SEM.

RESULTS

EPO Treatment Regimen Has No Effect on Body Weight or Fat Mass During DIO

EPO treatment of obese mice reduces body weight and fat mass after 3–4 weeks (35). Considering that body weight and fat mass changes influence WAT inflammation and Mϕ infiltration, affecting glucose tolerance and insulin sensitivity (1,244), we chose short-term EPO treatment regimen (<3 weeks) after obesity induction. Obese, insulin-resistant, glucose-intolerant mice, fed an HFD for 12 weeks, were EPO treated during the last 2 weeks of the study with no detectable effects on body weight, body weight gain, fat mass, perigonadal fat weight, or serum leptin levels (Fig. 1A–E). Consistent with previous reports (35), prolonged EPO administration (≥3 weeks) reduced body weight (Fig. 1F). All subsequent studies were conducted using the 2-week regimen of EPO treatment.

EPO Treatment Attenuates Insulin Resistance and Glucose Intolerance During DIO

We investigated whether EPO treatment can ameliorate existent systemic insulin resistance and glucose intolerance associated with DIO using ITT and GTT. EPO improved both (Fig. 2A and B), with striking reduction in fasting blood glucose levels (Fig. 2C) and impressive effects on glucose tolerance (Fig. 2B). EPO increased hematocrit (Fig. 2D); however, serum glucose (Fig. 2E) and serum insulin (Fig. 2F) were also reduced, showing that total blood glucose reduction is
not the result of increased packed red cell volume. To examine insulin sensitivity of individual tissues, we performed euglycemic–hyperinsulinemic clamp studies. EPO-treated mice required higher glucose infusion rate (GIR) to maintain blood glucose during insulin infusion and exhibited higher whole body glucose disposal and glycogen synthesis rate compared with controls (Fig. 2G and H). Although these differences have not reached statistical significance, EPO significantly increased 2-deoxyglucose uptake in skeletal muscle but not WAT, brown adipose tissue, or heart (Fig. 2I and J). EPO had no effect on basal or clamp endogenous glucose production (Fig. 2H), suggesting no changes in liver insulin sensitivity. Taken together, these data demonstrate that EPO treatment, which had no effect on body weight, improved whole body insulin sensitivity primarily by enhancing glucose uptake in the skeletal muscles.

**EPO Treatment Inhibits WAT Inflammation and Reduces MΦ Infiltration**

Unlike WAT with high EPO-R expression in both adipocytes and SVF, EPO-R is not detectable in skeletal muscle (Fig. 3A and B), indicating that EPO indirectly stimulates glucose uptake in skeletal muscle. Although EPO had no effect on WAT insulin sensitivity, we noticed that it dramatically improved inflammation within adipose tissue, as indicated by the lack of crown structure around adipocytes in EPO-treated mice (Fig. 3C and D). This novel observation prompted us to study the role of EPO signaling in obesity-induced

---

**Figure 1**—A 2-week EPO treatment regimen does not affect body weight or fat mass. WT C57BL/6 male mice were fed an HFD for 12 weeks and treated with or without EPO (1,000 units/kg) for the final 2 weeks of the study. Lean mice + saline and obese mice + saline were used as negative and vehicle controls, respectively. Final body weight (A), body weight gain (B), fat mass (C), perigonadal fat mass (D), and serum leptin (E) were measured for all three groups at the end of week 12. F: WT C57BL/6 mice with obesity induced by HFD feeding for 13 weeks were treated with or without EPO (1,000 units/kg) every 48 h during the final 3 weeks of the study. Lean mice + saline were used as negative controls. Results are shown as mean ± SEM for n = 8 mice per group, representative of three independent experiments with similar results. *P < 0.05.
inflammation. We performed comprehensive gene expression profiling of cytokines and chemokines in SVF. EPO reduced Cd1, Cd2, Cd3, and Cd22 expression levels but not IL-10 (Fig. 3E). Protein analysis showed that EPO treatment reduced TNF-α—consistent with the role of TNF-α during obesity-induced insulin resistance (45)—increased IL-10 (Fig. 3F), and downregulated CCL1, CCL2, CCL3, and CCL22 levels (data not shown).

Mϕ are responsible for the majority of EPO-R expression in SVF (Fig. 3G), and EPO treatment reduced total Mϕ percentage and number by ~11.2 and ~30%, respectively (Fig. 3H and I), supporting an inhibitory effect for EPO on WAT inflammation. Mϕ are the main responders in SVF, as T-cell and B-cell percentage showed no detectable changes after EPO treatment (Supplementary Table 2). Consistent with results showing Mϕ as predominant EPO-R

---

**Figure 2**—EPO treatment attenuates insulin resistance and glucose intolerance during DIO. WT C57BL/6 mice with obesity induced by HFD feeding for 12 weeks were treated with or without EPO (1,000 units/kg) every 48 h during the final 2 weeks of the study. Lean mice + saline were used as negative controls. A: For ITT, glucose levels were measured after intraperitoneal injection of 1 unit/kg insulin. B: For GTT, glucose levels were measured after intraperitoneal injection of 1 g/kg glucose. Fasting glucose levels (C), percentage hematocrit (D), serum glucose levels (E), and serum insulin levels (F) were measured. All measurements were performed at the end of week 12. Euglycemic–hyperinsulinemic clamps were performed in DIO mice fasted overnight after 2 weeks of EPO treatment (n = 5–8/group). G: GIR. H: Whole-body glucose fluxes, GIR, endogenous glucose production, and glucose disposal. I and J: Tissue 2-deoxyglucose update measured during clamp. Clamp plasma glucose levels were 209 ± 39 and 157 ± 13 mg/dL in saline- and EPO-treated mice, respectively. Clamp plasma insulin levels were 6.6 ± 2.3 ng/mL in saline-treated mice and 5.8 ± 0.8 ng/mL EPO-treated mice. Results are shown as mean ± SEM for n = 8 mice per group, representative of three independent experiments with similar results. *P < 0.05. BAT, brown adipose tissue; EGP, endogenous glucose production; Epi, epididymal; Ing, inguinal; Rd, glucose disposal.
expressing cells in SVF (Fig. 3G), EPO-treated animals exhibited reduced Mφ infiltration associated with decreased EPO-R expression in WAT (Fig. 3J), providing a further link between WAT Mφ and EPO/EPO-R response.

EPO/EPO-R Signaling Induces Stat3 Phosphorylation in Mφ and Inhibits Their Inflammatory Response In Vitro
To investigate EPO/EPO-R signaling in WAT Mφ and its direct effects on their inflammatory responses, Mφ sorted from obese SVF were cultured in EPO-coated plates for 15 min, fixed, and analyzed by phosphoflow. Although p-Stat5 and p-Stat6 were not detected in WT Mφ upon EPO treatment (Fig. 4A), EPO induced Stat3 phosphorylation (Fig. 4B). These findings were further confirmed by Western blotting (data not shown). EPO-R absence in ΔEpoR Mφ prevented their response to EPO as shown by the absence of p-Stat3 (Fig. 4B, top right) compared with WT (Fig. 4B, top left). Moreover, treatment of WAT Mφ with EPO (5 units/mL) for 24 h reduced proinflammatory genes expression of TNF-α and iNOS and markedly increased anti-inflammatory cytokine IL-10 expression (Fig. 4C and D), collectively confirming a direct response by WAT Mφ to EPO/EPO-R signaling.

EPO Treatment Reverses Obesity-Induced Shift in Mφ Population Subtypes
The effect of EPO administration on Mφ population subtypes in WAT was examined. Using flow cytometry, EPO decreased MGL-1⁺/CD11c⁻ while increasing MGL-1⁺ Mφ (Fig. 5A and B). qRT-PCR confirmed phenotypic Mφ shift (Fig. 5C and D), showing that EPO reduced iNOS and IL-1β and increased Fizz-1, Ppar-γ, and Arg-1. Overall, EPO increased M2-like Mφ and reduced M1-like Mφ numbers, thus identifying and confirming its role in the regulation of not only Mφ infiltration, but also local subtype polarization. Whether or not the conversion of M1- to M2-like Mφ, as recently suggested (46), contributes to the observed EPO-mediated increase in MGL-1⁺ Mφ remains unknown. Since M1/M2 nomenclature of Mφ is based on in vitro studies, and may not represent in vivo Mφ subtypes (17), we use the designation M1- and M2-like Mφ to describe F4/80⁺MGL-1⁻ and MGL-1⁺ cells, respectively.

Cellular Responses Drive EPO-Mediated Reversal of Mφ Subtype Shift
M1 Mφ infiltrating the WAT during DIO originate from circulating Ly6ch⁺CCR2⁺ inflammatory monocytes in a CCL2/CCR2-dependent manner (5,6,8). EPO lowers Ccl2...
expression levels in WAT (Fig. 3C). We predicted EPO-mediated reduction of M1-like Mφ subset (Fig. 5A and B) to be associated with fewer circulating Ly6ChICCR2+ monocytes and reduced local WAT and serum CCL2 levels. This was confirmed by flow cytometric analysis of whole blood (Fig. 6A and B) and measurement of local WAT and serum CCL2 protein levels (Fig. 6C).

M2 Mφ have been suggested to self-generate via proliferation in the presence of IL-4 in vivo (46,47). To study how the observed EPO-mediated expansion of M2-like
Mφ may occur (Fig. 5), quantitative comparisons of EPO- and saline-treated obese animals were performed. Ki-67 staining and BrdU uptake showed that EPO promotes MGL-1+ Mφ proliferation (Fig. 6D) in association with an increase in serum and WAT IL-4 (Fig. 6E). We confirmed this in obese Stat6−/− and IL-4−/− mice, reported previously to have defective M2-like Mφ (48–50). EPO treatment failed to expand M2-like Mφ in these animals (Fig. 6F) unlike controls (Figs. 5B and 6F). These findings highlight a previously unrecognized role for EPO/EPO-R in the regulation of Mφ polarization in vivo, where IL-4/Stat6 axis is indispensable for EPO-mediated M2-like Mφ expansion.

**Endogenous EPO/EPO-R Signaling Regulates Mφ Infiltration and Subtype Shift**

To investigate the role of endogenous EPO/EPO-R signaling during obesity-induced WAT inflammation, we used DIO in ΔEpoR mice (39). The absence of EPO-R expression in ΔEpoR WAT (adipocytes and SVF) and Mφ were confirmed (Figs. 3B and 7A). ΔEpoR mice maintained on normal chow become obese and glucose intolerant as they
Baseline measurements prior to the onset of HFD feeding showed ΔEpoR mice (6–8 weeks old) to have slightly higher body weight and fat mass compared with age-matched WT controls (Fig. 7B). However, after 12 weeks of HFD feeding, there was no significant difference in final body weight or fat mass between ΔEpoR and their age-matched WT controls (Fig. 7B).

Mφ express the highest level of EPO-R mRNA among immune cell subsets profiled here (Fig. 7C) and are the only EPO responsive population of immune cells in WT animals (Supplementary Table 2). ΔEpoR animals with DIO showed higher circulating inflammatory monocyte numbers (Fig. 7D), suggesting a possible direct role for endogenous EPO/EPO-R signaling in the regulation of WAT inflammation independently of its effect on body weight and fat mass. ΔEpoR SVF cell chemokine and cytokine expression profiles showed elevated levels of Ccl1, Ccl2, Ccl12, Ccl17, Ccl19, Ccl22, Cxcl10, and Cxcl11, with unchanged Ccl3, TNF-α, and IL-10 (Fig. 7E). Protein profiling confirmed the upregulation of these chemokines, including CCL1 (data not shown). Despite unchanged TNF-α and IL-10 mRNA levels, we found higher TNF-α and similar IL-10 protein levels in ΔEpoR animals (Fig. 7F).
CCL2 levels in ΔEpoR exceeded those in WT controls (Fig. 7F), where the difference in local WAT CCL2, but not serum, was significant (P < 0.05). Flow cytometry and histology showed increased total Mϕ, denser inflammatory infiltrates and crown-like-structure formation, and more MGL-1+Mϕ and fewer MGL-1+Mϕ in WAT (Fig. 7G–I). The latter was confirmed via qRT-PCR (Fig. 7J). Despite reduced M2-like Mϕ numbers in WAT of ΔEpoR (Fig. 7I), serum and WAT IL-4 levels were not lower than WT controls (Fig. 7K). Based on Ki-67 staining the percentage of proliferating MGL-1+ cells in ΔEpoR SVF was lower than their WT counterparts (data not shown).

**DISCUSSION**

Herein, we characterized the role of EPO/EPO-R during obesity-induced WAT inflammation and insulin resistance. Our observations reveal novel and unexpected role for EPO/EPO-R in regulating M1-like Mϕ infiltration, M2-like Mϕ expansion in WAT, and inflammatory monocyte recruitment (Figs. 3 and 5–7) prior to any body...
Figure 6—EPO treatment decreases circulating inflammatory monocytes and promotes WAT M2-like Mφ expansion. Dot plots for flow cytometry analysis of circulating blood inflammatory monocytes Ly6C<sup>hi</sup>CCR2<sup>+</sup> (A) and their numbers per milliliter of blood (B) are shown, as well as CCL2 levels in serum and perigonadal WAT lysates (C). D: Flow cytometry results depict the percentage of proliferating MGL-1<sup>+</sup> versus MGL-1<sup>-</sup> Mφ in perigonadal SVF, based on Ki-67 staining (left) and BrdU uptake (right). E: Serum and WAT IL-4 levels are shown. F: Numbers of total Mφ (bar) and MGL-1<sup>+</sup> (top, black) and MGL-1<sup>-</sup> (bottom, gray) Mφ subsets per gram of perigonadal WAT from WT, Stat6<sup>−/−</sup>, and IL-4<sup>−/−</sup> mice are shown. Results are presented as mean ± SEM for n = 4–6 mice per group, representative of two or three independent experiments with similar results. *P < 0.05; **P < 0.01.
weight or fat mass loss (Fig. 1). We propose that the anti-inflammatory effects of EPO in WAT occur in association with its regulation of systemic glucose metabolism and that it is not restricted to exogenous high-dose EPO treatment, as endogenous EPO is sufficient to regulate WAT inflammation.

We and others have reported the reduction in blood glucose with high-dose EPO treatment and transgenic overexpression using mouse models of DIO and insulin resistance (35–38). The improved glucose metabolism is associated with reduced body weight gain and fat mass accumulation, where EPO administration was initiated at...
the onset of HFD feeding and continued for 3 weeks or longer (35–37). In stark contrast, herein, EPO administration was initiated after DIO, and its associated insulin resistance and glucose intolerance have already been established and followed a 2-week duration regimen. We report improvements in glucose metabolism that precede any detectable reduction in body weight or fat mass (Fig. 1), suggesting the EPO-mediated effects observed here are independent from the role in body weight and fat mass regulation.

The shift to increased fat oxidation in muscle has been shown to contribute to the observed normalization of glucose sensitivity with EPO (38). These studies are consistent with our finding that EPO increased glucose uptake in skeletal muscle. Moreover, EPO was shown to protect against diabetes through direct effects on pancreatic β-cells in mouse models of types 1 and 2 diabetes not including DIO (36,37,40).

Herein, anti-inflammatory effect of EPO is identified and its signaling in Mϕ and effect on their activation and infiltration are characterized. Indeed, it is known that obesity-induced WAT inflammation is linked to increased systemic inflammation and insulin resistance (1–4). We demonstrate that EPO/EPO-R signaling in WAT Mϕ promotes Stat3 phosphorylation with clear anti-inflammatory effects (Fig. 4B and C), confirming a direct role in the regulation of Mϕ response. Interestingly, Stat3 phosphorylation does not appear to be sufficient, in the absence of Stat6, to mediate EPO/EPO-R signaling effect on M2-like Mϕ, as EPO treatment failed to expand this Mϕ.
subset in WAT of obese Stat6$^{-/-}$ mice (Fig. 6F), demonstrating a requirement for IL-4/Stat6 axis during EPO-mediated M2-like Mϕ expansion. In contrast, EPO treatment markedly reduced total and M1-like WAT Mϕ populations in obese Stat6$^{-/-}$ mice and IL-4$^{-/-}$ mice (Fig. 6F), indicating that EPO/EPO-R/p-Stat3 axis may be sufficient to inhibit the proinflammatory response. Collectively, we conclude that both direct (Fig. 4B and C) and indirect via IL-4/Stat6 (Fig. 6F) responses of WAT Mϕ to EPO/EPO-R are involved in mediating the observed anti-inflammatory effects (Figs. 3 and 5–7).

Considering our observations that Mϕ are EPO responsive, we propose that a direct contribution of their EPO/EPO-R signaling plays a major role in the inhibition of obesity-induced WAT inflammation. However, involvement of indirect EPO/EPO-R signaling in adipocytes on obesity-induced WAT inflammation cannot be entirely excluded, and its further investigation is required. Since EPO/EPO-R signaling appears to regulate TNF-α levels (Figs. 3 and 7), the change in TNF-α may be linked to EPO effects on insulin resistance and glucose intolerance (Figs. 2 and 8). The exact molecular networks driving this link, such as the role of JAK/STAT pathway and Akt activation downstream of EPO-R signaling, including the possibility of insulin sensitivity regulation by directly affecting signaling downstream of insulin receptor, require further studies.

Antiapoptotic and tissue-protective activities have been suggested to drive the anti-inflammatory effects of EPO indirectly rather than via direct modulation of immune cell function/response (32). Evidence in support of direct EPO effects on immune cells also exists.
Figure 8—Endogenous EPO/EPO-R signaling and glucose metabolism during DIO. A: For ITT, glucose levels were measured after intraperitoneal injection of 1 unit/kg insulin. B: For GTT, glucose levels were measured after intraperitoneal injection of 1 g/kg glucose. Fasting glucose (C) and serum insulin (D) levels were determined. ΔEpoR mice with DIO, induced by 12 weeks of HFD feeding, were injected subcutaneously with saline or EPO (1,000 units/kg) every 48 h for the final 2 weeks of HFD feeding, and hematocrit (E), ITT (F), GTT (G), and flow cytometry analysis of perigonadal fat SVF cells (H) were determined. All measurements were performed at the end of week 12. Data presented as mean ± SEM for n = 8 mice per group, representative of three independent experiments with similar results. *P < 0.05.
Erythropoietin and Obesity-Induced Inflammation.

In summary, our studies demonstrate the involvement of EPO/EPO-R signaling in the reversal of insulin resistance and glucose intolerance; uncouple its role in obesity, body weight, and fat mass regulation from its effect on inflammation; and collectively identify and characterize the anti-inflammatory effects of EPO. We reveal a previously unrecognized role for EPO in the expansion of M2-like Mϕ population via IL-4/Stat6 axis and for Stat3 activation in the anti-inflammatory effects of EPO-R in WAT Mϕ. These findings highlight a novel EPO/EPO-R signaling-mediated regulation pathway of WAT inflammation in prediabetic condition, thus adding to its reported “anti-diabetic” effects shown to act via cytoprotection of pancreatic islet β-cells (40) or muscle fat oxidation (38) in experimental models of diabetes.

Acknowledgments. The authors thank William Jou at the National Institute of Diabetes and Digestive and Kidney Diseases Intramural Program Mouse Metabolism Core Facility for his excellent technical assistance with metabolic studies.

Funding. This work was supported by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institutes of Health.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. M.A. designed experiments, conducted the studies, analyzed the data, and wrote the manuscript. B.M.R., O.G., R.T., and T.C. contributed to data generation and analysis and reviewed and edited the manuscript. C.T.N. contributed to experiment design and data discussion and reviewed and edited the manuscript. M.A. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References

1. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010;72:219–246
2. Zeyda M, Stulnig TM. Obesity, inflammation, and insulin resistance—a mini-review. Gerontology 2009;55:379–386
3. de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett 2008;582:97–105
4. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest 2011;121:2111–2117
5. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007;117:175–184
6. Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 2007;56:16–23
7. Wentworth JM, Naselli G, Brown WA, et al. Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity. Diabetes 2010;59:1648–1656
8. Lumeng CN, DelProposto JB, Westcott DJ, Saltiel AR. Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes 2008;57:3239–3246
9. Kande H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006;116:1494–1505
10. Kamei N, Tobe K, Suzuki R, et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 2006;281:26602–26614
11. Arkan MC, Hevener AL, Greten FR, et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005;11:191–198
12. Odegaard JJ, Ricordo-Gonzalez RR, Goforth MH, et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007;447:1116–1120
13. Hevener AL, Olefsky JM, Reichart D, et al. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest 2007;117:1658–1669
14. Mauer J, Chaurasia B, Plum L, et al. Myeloid cell-restricted insulin receptor deficiency protects against obesity-induced inflammation and systemic insulin resistance. PLoS Genet 2010;6:e1000938
15. Kiefer FW, Zeyda M, Gollinger K, et al. Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes 2010;59:935–946
16. Feral CC, Neels JG, Kummer C, Slępak M, Olefsky JM, Ginsberg MH. Blockade of alpha4 integrin signaling ameliorates the metabolic consequences of high-fat diet-induced obesity. Diabetes 2008;57:1842–1851
17. Westcott DJ, DelProposto JB, Geletka LM, et al. MGL1 promotes adipose tissue inflammation and insulin resistance by regulating 7/4/9i monocytes in obesity. J Exp Med 2009;206:3143–3156
18. Nishimura S, Manabe I, Nagasaki M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 2009;15:914–920
19. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 1995;95:2409–2415
20. Heilbronn LK, Campbell LV. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr Pharm Des 2008;14:1225–1230
21. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796–1808
22. Ebert BL, Bunn HF. Regulation of the erythropoietin gene. Blood 1999;94:1864–1877
23. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992;12:5457–5454
24. Semenza GL. Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis. Blood 2009;114:2015–2019
25. Sohmiya M, Kakiba T, Kato Y. Therapeutic use of continuous subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy. Eur J Endocrinol 1998;139:367–370
26. Noguchi CT, Wang L, Rogers HM, Teng R, Jia Y. Survival and proliferative deficiency protects against obesity-induced inflammation and systemic insulin resistance. PLoS Genet 2010;6:e1000938
27. Kertesz N, Wu J, Chen TH, Sucov HM, Wu H. The role of erythropoietin in cardiac morphogenesis. Development 2007;134:1985–1994
28. Wu H, Lee SH, Gao J, Liu X, Iruela-Arispe ML. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 1999;126:3597–3605
29. Yu X, Shacka JJ, Eells JB, et al. Erythropoietin receptor signalling is required for normal brain development. Development 2002;129:505–516
30. Ueda K, Takano H, Nitsumiya Y, et al. Sonic hedgehog is a critical mediator of erythropoietin-induced cardiac protection in mice. J Clin Invest 2010;120:2016–2029.
31. Bernaudin M, Marli HH, Roussel S, et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 1999;19:643–651.
32. Villa P, Bigini P, Mennini T, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003;198:971–975.
33. Nairz M, Schroll A, Moschen AR, et al. Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-κB-inducible immune pathways. Immunity 2011;34:61–74.
34. Yuan R, Maeda Y, Li W, Lu W, Cook S, Dowling P. Erythropoietin: a potent inducer of peripheral immune inflammatory modulation in autoimmune EAE. PLoS One 2008;3:e1924.
35. Foskett A, Alnaeeli M, Wang L, Teng R, Noguchi CT. The effects of erythropoietin dose titration during high-fat diet-induced obesity. J Biomed Biotechnol 2011;2011:373781.
36. Teng R, Gavrilova O, Suzuki N, et al. Disrupted erythropoietin signalling promotes obesity and alters hypothalamic proopiomelanocortin production. Nat Commun 2011;2:520.
37. Katz O, Stuible M, Golishevski N, et al. Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models. J Endocrinol 2010;205:87–95.
38. Højman P, Brolin C, Gissel H, et al. Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles. PLoS ONE 2009;4:e5894.
39. Suzuki N, Ohneda O, Takahashi S, et al. Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 2002;100:2279–2288.
40. Choi D, Schroer SA, Lu SY, et al. Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. J Exp Med 2010;207:2831–2842.
41. Wang R-H, Kim H-S, Xiao C, Xu X, Gavrilova O, Deng CX. Hepatic Sirt1 deficiency in mice impairs mTORc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. J Clin Invest 2011;121:4477–4490.
42. King IL, Dickendesher TL, Segal BM. Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood 2009;113:3190–3197.
43. Kruzhik PD, Nolan GP. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A 2003;55:61–70.
44. Kosteli A, Suguru E, Haemmerle G, et al. Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue. J Clin Invest 2010;120:3466–3479.
45. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006;116:1793–1801.
46. Jenkins SJ, Ruckerl D, Cook PC, et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 2011;332:1284–1288.
47. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity 2010;32:593–604.
48. Brombacher F, Arendse B, Peterson R, Hölscher A, Hölscher C. Analyzing classical and alternative macrophage activation in macrophage/neutrophil-specific IL-4 receptor-α-deficient mice. Methods Mol Biol 2009;531:225–252.
49. Herbert DR, Hölscher C, Mohrs M, et al. Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology. Immunity 2004;20:623–635.
50. Takeda K, Tanaka T, Shi W, et al. Essential role of Stat6 in IL-4 signalling. Nature 1996;380:627–630.